about
Prevalence and clinical significance of heparin induced antibodies in chronic hemodialysis patients and cardiac surgery patients.Dialysis by the book? Treatment of renal failure in a 101-year-old patientMDR-1-overexpression in HT 29 colon cancer cells grown in SCID mice.Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.Long-Term Hypoparathyroidism and Hypophosphatemia in Dialysis PatientsInfluence of minimal changes in preoperative renal function on outcomes of cardiac surgery.Preoperative renal dysfunction and clinical outcomes of cardiac surgery in octogenarians.Mild hyponatremia is associated with functional and cognitive decline in chronic hemodialysis patients.Use of pregabalin in the management of chronic uremic pruritus.Prevention of scarring in experimental pyelonephritis in the rat by early antibiotic therapyThe labile iron pool of hepatocytes in chronic and acute iron overload and chelator-induced iron deprivationUrokinase for restoration of patency of occluded permanent central venous access in haemodialysis patients--a new protocolAcute increase in blood urea nitrogen caused by enteric nutritionUse of enoxaparin to diminish the incidence of vascular access stenosis/thrombosis in chronic hemodialysis patientsNeutrophil gelatinase-associated lipocalin as a predictor of complications and mortality in patients undergoing non-cardiac major surgeryUrinary neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury in geriatric patients with urinary tract infection treated by colistinPegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer
P50
Q33398916-BFDCA164-2E99-47C1-BFA7-F9259A3222CCQ37391540-51D07110-D8A9-4A9D-9451-86D4CEA2DFB6Q39431256-2B78BAAF-262C-4202-909A-24D7C084615FQ40170302-D9468EE1-1A11-4E5D-9B5F-462595FFB7CEQ40479039-D2C78E1C-65AF-46E8-91E7-FDFDCDC589EFQ43574329-FC39C467-38D2-4E3A-AA81-C8B5C6F3BE42Q43755138-3B152129-906F-4055-9D3C-5536EA801D91Q44252263-6DA15138-B584-49CF-B0FE-E818B7260CC7Q47359210-4FDE495C-B56F-4247-9681-3EF6A553CDC9Q70411240-262D8F5D-ED4D-429D-9DA9-B2AABB1BC67DQ77530290-3E025775-BF3A-4079-9485-FFCD63C2E10AQ79181892-01EF3436-E545-428E-ABC6-37621790F196Q80069177-316534D3-A309-4070-BAEC-193FE93216C2Q82455987-3DFF4961-313F-4075-AA62-EB629DA04658Q83395726-D665D1F9-A6F6-49DE-950C-F8325B2FF445Q86517793-0DC88FC7-AF33-4214-96A2-D36C17ABE827Q87018944-64D45ECE-081F-49F2-924A-AE0FB457A691
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Itzchak Slotki
@ast
Itzchak Slotki
@en
Itzchak Slotki
@es
Itzchak Slotki
@nl
Itzchak Slotki
@sl
type
label
Itzchak Slotki
@ast
Itzchak Slotki
@en
Itzchak Slotki
@es
Itzchak Slotki
@nl
Itzchak Slotki
@sl
prefLabel
Itzchak Slotki
@ast
Itzchak Slotki
@en
Itzchak Slotki
@es
Itzchak Slotki
@nl
Itzchak Slotki
@sl
P106
P2798
P31
P496
0000-0002-5261-0500
P569
2000-01-01T00:00:00Z